Current Document Type: HighlightsVideoPage Daratumumab, Pomalidomide, and Dexamethasone for Multiple Myeloma Treatment - JADPRO

Watch More Highlights

Beth Faiman, PhD, MSN, APRN-BC, AOCN, FAAN, of the Taussig Cancer Institute, Cleveland Clinic, discusses what advanced practitioners need to know about phase III findings on subcutaneous daratumumab plus pomalidomide and dexamethasone. Compared to pomalidomide and dexamethasone alone, this combination reduced the risk of disease progression or death by 37% for patients with relapsed or refractory multiple myeloma (Abstract 412).

Copyright © 2010-2022 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.